Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving ...

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Value Investor model based on the published strategy of ...

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history.

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Nov 17 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on ...

Hims & Hers Health (HIMS) announced on Monday an up to $250M share repurchase program of outstanding class A common stock over the next three years. Shares were +2.76% pre-market to $38.00. The ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...